Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector

Gene Therapy

Volumn 5, Issue 5, 1998, Pages 635-644

  Richardson, J H ^a   Hofmann, W ^a   Sodroski, J G ^a   Marasco, W A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

IL 2R ; IRES; Lentivirus vector; Single chain antibody; VSV G protein

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECEPTOR ANTIBODY;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; MARKER GENE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RIBOSOME; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS; VIRUS ENVELOPE;

AMPHOTROPIC MURINE LEUKEMIA VIRUS; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MURINAE; VESICULAR STOMATITIS VIRUS;

EID: 0031832695     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300644     Document Type: Article

References (60)

1. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-982.
2. Ross G et al. Gene therapy in the United States: a five-year status report. Hum Gene Ther 1996; 7: 1781-1790.
3. Roe TY, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends upon mitosis. EMBO J 1993; 12: 2099-2108.
4. Lewis PF, Emerman M. Passage through mitosis is required for onco-retroviruses but not the human immunodeficiency virus. J Virol 1994; 68: 510-516.
5. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992; 11: 3053-3058.
6. Burinsky MJ et al. Active nuclear import of human immunodeficiency virus type 1 pre-integration complexes. Proc Natl Acad Sci USA 1992; 89: 6580-6584.
7. Li G, Simm M, Potash MJ, Volsky DJ. Human immunodeficiency virus type 1 DNA synthesis, integration and efficient viral replication in growth-arrested T cells. J Virol 1993; 67: 3969-3977.
8. Bukrinsky MI et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365: 666-669.
9. Gallay P, Swingler S, Aiken C, Trono D. HIV-1 infection of non-dividing cells: C-terminal ryrosine phosphorylation of the viral matrix protein is a key regulator. Cell 1995; 80: 379-388.
10. Heinzinger NK et al. The vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing cells. Proc Natl Acad Sci USA 1994; 91: 7311-7315.
11. Reiser J et al. Transduction of nondividing cells using pseudotyped high-titer HIV type 1 particles. Proc Natl Acad Sci USA 1996; 93: 15266-15271.
12. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263- 267.
13. Landau NR, Page KA, Littman DR. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 1991; 65: 162-169.
14. Kimpton J, Emerman M. Detection of replication-competent and pseudo-typed human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 1992; 66: 2232-2239.
15. Lusso P, Lori F, Gallo RC. CD4-independent infection by human immunodeficiency virus type 1 after phenotypic mixing with human T-cell leukemia viruses. J Virol 1990; 64: 6341-6344.
16. Zhu Z, Chen SSL, Huang SH. Phenotypic mixing between human immunodeficiency virus and vesicular stomatitis virus or herpes simplex virus. J AIDS 1990; 3: 215-219.
17. + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 1996; 70: 2581-2585.
18. 2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol 1996; 70: 2324-2331.
19. Yee JK et al. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91: 9564-9568.
20. Emerman M, Temin H. Genes with promoters in retrovirus vector scan be independently suppressed by an epigeneric mechanism. Cell 1984; 39: 459-467.
21. Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acids Res 1986; 14: 9318-9396.
22. Bowtell DD, Cory S, Johnson GR, Gonda TJ. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J Virol 1988; 62: 2464-2473.
23. Dougherty JP, Temin HM. High mutation rate of a spleen necrosis virus-based retrovirus vector. Mol Cell Biol 1986; 168: 87-95.
24. Adam MA, Ramesh N, Miller DA, Osborne WRA. Internal initiation of translation in retroviral vectors carrying picorna-virus 5′ nontranslated regions. J Virol 1991; 65: 4985-4990.
25. Chen BF, Hwang LH, Chen DS. Characterization of a bicistronic retroviral vector composed of the swine vesicular disease virus internal ribosome entry site. J Virol 1993; 67: 2142-2148.
26. Koo HM et al. A spleen necrosis virus-based retroviral vector which expresses two genes from a dicistronic mRNA. Virology 1992; 186: 669-675.
27. Levin R et al. Inhibition of early and late events of the HTV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17. Molec Med 1997; 2: 96-110.
28. Aran JM, Gottesman MM, Pastan I. Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA 1994; 91: 3176-3180.
29. Morgan RA et al. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res 1992; 20: 1293-1299.
30. Rosen CA. Regulation of HIV gene expression by RNA-protein interactions. Trends Genet 1991; 7: 9-14.
31. Zack JA et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-222.
32. Zack JA, Haislip AM, Krogstad P, Chen ISY. Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol 1992; 66: 1717-1725.
33. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995; 69: 2977- 2988.
34. + T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol 1995; 69; 5659-5665.
35. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV- 1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9: 1551-1560.
36. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV- 1 infection. Science 1991; 254: 423-427.
37. Jang SK, Davies MV, Kaufman RJ, Wimmer E. Initiation of protein synthesis by internal entry of ribosomes into the 5′ nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol 1989; 63: 1651-1660.
38. Richardson JH, Sodroski JG, Waldmann TA, Marasco WA. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the α subunit of the receptor. Proc Natl Acad Sci USA 1995; 92: 3137-3141
39. Richardson JH, Waldmann TA, Sodroski JG, Marasco WA. Inducible knockout of the interleukin-2 receptor α. chain: expression of the high-affinity IL-2 receptor is not required for the in vitro growth of HTLV-I-transformed cell lines. Virology 1997; 237: 209-216.
40. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function and target genes. Annu Rev Immunol 1993; 11: 245-267.
41. Cullen BR. Regulation of HIV gene expression. AIDS 1995; 9 (Suppl. A): S19-S32.
42. Choi T, Huang M, German C, Jaenisch R A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991; 11: 3070-3074.
43. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478-482.
44. Chuah MK, Vandendriessche T, Morgan RA. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 1995; 6: 1363-1377.
45. Huang MT, German CM. Intervening sequences increase efficiency of RNA 3′ processing and accumulation of cytoplasmic RNA. Nucleic Acids Res 1990; 18: 937-947.
46. + T cells. Eur J Immunol 1996; 26: 2263-2270.
47. Willerford DM et al. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3: 521-530.
48. Hori T et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987; 70: 1069-1072.
49. Poznansky M et al. Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector. J Virol 1991; 5: 532-536.
50. Tiley LS et al. Visna virus encodes a post-transcriptional regulator of viral structural gene expression. Proc Natl Acad Sci USA 1990; 87: 7497-7501.
51. Page KA, Landau MR, Littman DR. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 1990; 64: 5270-5276.
52. Brody BA, Hunter E. Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol 1992; 66: 3422-3475.
53. Flugel RM, Rethwilm A, Maurer B, Darai G. Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes. EMBO J 1987; 6: 2077-2084.
54. Helseth E et al. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J Virol 1990; 64: 2416-2420.
55. Hafler DA, Buchsbaum M, Johnson D, Weiner HL. Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 1985; 18: 451-458.
56. Robert-Guroff M et al. Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol 1990; 64: 3391-3398.
57. Swartz S et al. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol 1990; 64: 2519-2529.
58. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication and infectivity. J Virol 1993; 67: 6365- 6378.
59. Gaynor RB. Regulation of HIV-1 gene expression by the transactivator protein Tat. Curr Top Microbiol Immunol 1995; 193: 51-77.
60. Jones KA. Taking a new TAK on tat transactivation. Genes Dev 1997; 11: 2593-2599.